elita
| Field | Value | Source |
|---|---|---|
| cohort_size | total=5, affected_treated=5 | Table 1 |
| cohort_demographics | breeds=[Miniature long-haired Dachshunds], age_range=10-21mo, sex=not_reported, weight=not_reported | Materials and Methods, Animals section |
| endpoint_definition | neurological end-stage disease | Materials and Methods, CNS gene therapy treatment |
| study_design | longitudinal observational study of gene therapy treated dogs | Abstract |
| data_granularity | summary_statistics_only | Statistical analyses section |
| H/BW % | Affected Treated | 10mo | mean=0.76, n=2 | Table 1 |
| H/BW % | Affected Treated | 18mo | mean=1.03, n=2 | Table 1 |
| H/BW % | Affected Treated | 21mo | 0.94, n=1 | Table 1 |
| LV+S/RV | Affected Treated | 10mo | mean=3.02, n=2 | Table 1 |
| LV+S/RV | Affected Treated | 18mo | mean=2.38, n=2 | Table 1 |
| LV+S/RV | Affected Treated | 21mo | 2.42, n=1 | Table 1 |
| RV/BW % | Affected Treated | 10mo | mean=0.17, n=2 | Table 1 |
| RV/BW % | Affected Treated | 18mo | mean=0.25, n=2 | Table 1 |
| RV/BW % | Affected Treated | 21mo | 0.24, n=1 | Table 1 |
| LV+S/BW % | Affected Treated | 10mo | mean=0.515, n=2 | Table 1 |
| LV+S/BW % | Affected Treated | 18mo | mean=0.605, n=2 | Table 1 |
| LV+S/BW % | Affected Treated | 21mo | 0.59, n=1 | Table 1 |
| RV/TC % | Affected Treated | 10mo | mean=22.4, n=2 | Table 1 |
| RV/TC % | Affected Treated | 18mo | mean=24.45, n=2 | Table 1 |
| RV/TC % | Affected Treated | 21mo | 25.7, n=1 | Table 1 |
| LV+S/TC % | Affected Treated | 10mo | mean=67.5, n=2 | Table 1 |
| LV+S/TC % | Affected Treated | 18mo | mean=57.85, n=2 | Table 1 |
| LV+S/TC % | Affected Treated | 21mo | 62.3, n=1 | Table 1 |
| Field | Value | Source |
|---|---|---|
| missing_individual_records | individual animal data points for blood chemistry and echocardiography are presented as summary graphs only | Statistical analyses section |
| missing_control_data | control group values for anatomical heart measurements are provided as a reference range only, not individual control animal data | Table 1 |
| Field | Value | Source |
|---|---|---|
| cohort_size | total=178, malignant_tumor_group=56, benign_tumor_group=82, healthy_control_group=40 | Abstract; Table 1 |
| cohort_demographics | breeds=not_reported, age_range=1-17yr, sex=female, weight=not_reported | Results, Epidemiological characteristics section; Table 1 |
| endpoint_definition | Diagnostic sensitivity, specificity, accuracy, and Youden index of serum CA15-3, CEA, and SF for canine mammary gland tumors | Abstract; Table 4 |
| study_design | Cross-sectional diagnostic accuracy study | Materials and method, Collection of samples section |
| data_granularity | summary_statistics_only | Table 2; Table 3; Table 4 |
| CA15-3 | Malignant | Baseline | mean=9.757, sd=5.832, unit=U/mL | Table 2 |
| CEA | Malignant | Baseline | mean=28.52, sd=19.07, unit=ng/mL | Table 2 |
| SF | Malignant | Baseline | mean=609.9, sd=236.5, unit=ng/mL | Table 2 |
| CA15-3 | Diagnostic Accuracy | Malignant | sensitivity=51.8pct, specificity=93.9pct, accuracy=76.8pct, AUC=0.751 | Table 4; Table 5 |
| CEA | Diagnostic Accuracy | Malignant | sensitivity=44.6pct, specificity=84.1pct, accuracy=68.1pct, AUC=0.680 | Table 4; Table 5 |
| SF | Diagnostic Accuracy | Malignant | sensitivity=62.5pct, specificity=85.4pct, accuracy=76.1pct, AUC=0.810 | Table 4; Table 5 |
| Combined_CA15-3_CEA_SF | Diagnostic Accuracy | Malignant | sensitivity=80.4pct, specificity=78.0pct, accuracy=80.0pct, AUC=0.838 | Table 4; Table 5 |
| Field | Value | Source |
|---|---|---|
| missing_analytes | No other serum chemistry or CBC analytes reported | Materials and method |
| unpublished_individual_records | Individual patient data not provided | Materials and method |
| Field | Value | Source |
|---|---|---|
| cohort_size | total=113, cPSS=24, HLEA=25, Controls=64 | Results, paragraph 2 |
| cohort_demographics | breeds=mixed_breed_predominant, age_range=not_reported, sex=not_reported, weight=not_reported | Results, paragraph 2 |
| study_design | retrospective_observational_study_using_left-over_serum_samples | Methods, Samples and groups |
| endpoint_definition | metabolomic_profiling_via_1H_NMR_spectroscopy | Methods, Serum metabolomic analyses |
| data_granularity | summary_statistics_only | Methods, Statistical analyses |
| classification_accuracy | simple_logistic_regression | accuracy=93.8pct, n=113 | Table 1 |
| Field | Value | Source |
|---|---|---|
| unpublished_individual_records | individual_metabolomic_data_points_not_provided | Data availability section |
| missing_control_data | bile_acid_concentrations_only_available_for_controls_<=3yr | Figure 1 caption |
| missing_histopathology | histopathological_diagnoses_for_HLEA_group_not_available | Discussion, Limitations |
| Field | Value | Source |
|---|---|---|
| cohort_size | total=191, epithelial=78, non-epithelial=77, miscellaneous=14, control=22 | Results section paragraph 2 |
| cohort_demographics | breeds=not_reported, age_range=not_reported, sex=not_reported, weight=not_reported | Results section paragraph 2 |
| endpoint_definition | survival_time_and_cause_of_death | Methods section, Survival analysis |
| study_design | prospective_observational_study | Results section paragraph 2 |
| data_granularity | summary_statistics_only | Methods section, Other statistical analysis |
| miR-214 | non-epithelial | baseline | AUC=0.83, n=77 | Results section paragraph 5 |
| miR-214 | sarcomas | baseline | AUC=0.92, sensitivity=81.5pct, specificity=90.9pct | Results section paragraph 5 |
| miR-214 | aggressive_sarcomas | baseline | AUC=0.94, sensitivity=81.6pct, specificity=95.5pct | Results section paragraph 5 |
| miR-214 | epithelial | baseline | AUC=0.75, sensitivity=56.8pct, specificity=63.6pct | Results section paragraph 5 |
| miR-126 | all_tumours | baseline | AUC=0.93, sensitivity=85.2pct, specificity=81.8pct | Results section paragraph 5 |
| miR-126 | epithelial | baseline | AUC=0.95, sensitivity=93.6pct, specificity=90.0pct | Results section paragraph 5 |
| Field | Value | Source |
|---|---|---|
| missing_individual_records | individual_animal_records_not_provided | Methods section |
| missing_timepoints | longitudinal_follow_up_data_not_provided_for_miRNA_levels | Methods section |
| Field | Value | Source |
|---|---|---|
| cohort_size | total=18, exceptional_responders=5, poor_responders=5 | Results section paragraph 2 and 3 |
| cohort_demographics | breeds=[Mixed, Australian Cattle Dog, English Bulldog, Labrador, Samoyed, Boerboel, Rottweiler], age_range=3-12yr, sex=8 spayed females, 9 castrated males, 1 intact male, weight_range=7.3-52.0kg | Results section paragraph 1 and Table 1 |
| endpoint_definition | Time to progression (TTP) defined as the interval between initiation of CHOP and cytologically confirmed disease relapse/progression | Materials and methods, Statistical analyses |
| study_design | Prospective cohort study | Materials and methods, Trial design and inclusion criteria |
| data_granularity | individual_animal_records | Table 1 |
| CMA1 | exceptional_responders | baseline | fold_change=17.125, p=0.000149 | Table 2 |
| IL2RB | exceptional_responders | baseline | fold_change=2.71948, p=0.01929 | Table 2 |
| CD34 | poor_responders | baseline | fold_change=-5.01556, p=0.025966 | Table 2 |
| CCL25 | poor_responders | baseline | fold_change=-10.6875, p=0.004531 | Table 2 |
| Field | Value | Source |
|---|---|---|
| missing_analytes | Full CBC and serum biochemistry values for individual patients were not provided in the text or tables | Results section paragraph 1 |
| missing_timepoints | Longitudinal data for all 18 patients at all timepoints (only 11 patients had paired naive and relapse samples) | Results section paragraph 3 |
| Field | Value | Source |
|---|---|---|
| cohort_size | total=21, ND=10, HFD=11 | Methods section, Study design |
| cohort_demographics | breeds=[mixed-breed, beagles], age_range=4-7yr, sex=mixed, weight=13-26kg, BCS=4-6 | Methods section, Dogs |
| endpoint_definition | Insulin sensitivity (SI) and beta cell compensation (AIRG) assessed via IVGTT; serum biochemistry; plasma lipidomics | Abstract |
| study_design | Randomized controlled trial, 12-week duration, ND vs HFD | Methods section, Study design |
| data_granularity | summary_statistics_only | Methods section, Statistical analysis |
| SI | ND | Week 12 | mean=11.5, unit=[mU/l]-1 min-1 | Abstract |
| SI | HFD | Week 12 | mean=4.7, unit=[mU/l]-1 min-1 | Abstract |
| AIRG | ND | Week 12 | mean=167.0, unit=[mU/l]min | Abstract |
| AIRG | HFD | Week 12 | mean=260.2, unit=[mU/l]min | Abstract |
| Cholesterol | ND | Week 12 | mean=187.9, sd=27.0, unit=mg/dL | Table 1 |
| Cholesterol | HFD | Week 12 | mean=235.7, sd=53.4, unit=mg/dL, p=0.019 | Table 1 |
| Leptin | ND | Week 12 | mean=1.6, sd=1.7, unit=ng/mL | Table 1 |
| Leptin | HFD | Week 12 | mean=8.6, sd=7.6, unit=ng/mL, p=0.012 | Table 1 |
| Triglycerides | ND | Week 12 | mean=54.1, sd=12.7, unit=mg/dL | Table 1 |
| Triglycerides | HFD | Week 12 | mean=77.5, sd=71.5, unit=mg/dL, p=0.310 | Table 1 |
| CE | ND | Week 8 | mean=1486.8, sd=173.7, unit=µM | Table 2 |
| CE | HFD | Week 8 | mean=1771.2, sd=331.2, unit=µM, p=0.024 | Table 2 |
| HCER | ND | Week 8 | mean=1.1, sd=0.2, unit=µM | Table 2 |
| HCER | HFD | Week 8 | mean=1.6, sd=0.3, unit=µM, p<0.001 | Table 2 |
| SM | ND | Week 8 | mean=313.6, sd=41.1, unit=µM | Table 2 |
| SM | HFD | Week 8 | mean=400.0, sd=62.3, unit=µM, p=0.001 | Table 2 |
| Field | Value | Source |
|---|---|---|
| unpublished_individual_records | Individual animal data for lipidomics and IVGTT parameters not provided | Methods section |
| missing_timepoints | Lipidomics only reported at week 0 and week 8, not week 12 | Methods section |
| Field | Value | Source |
|---|---|---|
| cohort_size | total=84, HC=37, KD=47 | Results section paragraph 2 |
| cohort_demographics | breeds=not_reported, age_range=not_reported, sex=not_reported, weight=not_reported | Results section paragraph 2 |
| endpoint_definition | KD defined by serum Cr > 1.5 mg/dL, BUN, urine color, and clinical diagnosis; HC defined by normal serum BUN (8.0-18.0 mg/dL) and Cr (0.1-0.9 mg/dL) | Methods section Animal patients |
| study_design | retrospective clinical study | Methods section Ethics statement |
| data_granularity | summary_statistics_only | Results section |
| miR-3107-5p | KD vs HC | N/A | fold_change=18.5, HC_raw=153, KD_raw=3674, HC_norm=6.7, KD_norm=10.9 | Table 1 |
| miR-486a-5p | KD vs HC | N/A | fold_change=13.91, HC_raw=142, KD_raw=2564, HC_norm=6.6, KD_norm=10.4 | Table 1 |
| miR-21a-5p | KD vs HC | N/A | fold_change=4.09, HC_raw=211, KD_raw=1120, HC_norm=7.2, KD_norm=9.2 | Table 1 |
| miR-10a-5p | KD vs HC | N/A | fold_change=2.31, HC_raw=3665, KD_raw=10999, HC_norm=13, KD_norm=14.1 | Table 1 |
| miR-10b-5p | KD vs HC | N/A | fold_change=2.16, HC_raw=11980, KD_raw=33624, HC_norm=11.3, KD_norm=12.5 | Table 1 |
| Field | Value | Source |
|---|---|---|
| unpublished_individual_records | individual animal data for clinical parameters and miRNA levels not provided | Methods section |
| missing_demographics | specific breed, age, and sex distribution for the 84 dogs not reported | Results section paragraph 2 |
| Field | Value | Source |
|---|---|---|
| cohort_size | total=150, CMGTs=112, control=38 | Results section paragraph 1 |
| cohort_demographics | breeds=not_reported, age_range=3-16yr, sex=female, weight=4-46kg | Results section paragraph 1 |
| endpoint_definition | Expression of serum/tissue IL-6, IL-8 and IL-10 in canine mammary gland tumors | Abstract |
| study_design | observational case-control study | Results section paragraph 1 |
| data_granularity | summary_statistics_only | Methods section |
| IL-6 | Control | Serum | mean=73.47, 95pctCI=66.78-78.38, unit=ng/L, range=42.8-107.9 | Results section paragraph 2 |
| IL-8 | Control | Serum | mean=377.8, 95pctCI=369.2-407.6, unit=ng/L, range=308.8-508.1 | Results section paragraph 2 |
| IL-10 | Control | Serum | mean=166.3, 95pctCI=165.8-203.8, unit=ng/L, range=113.1-299.2 | Results section paragraph 2 |
| IL-6 | Malignant | Serum | Age >=8 | mean=159.5, sd=46.14, unit=ng/L | Table 2 row 1 |
| IL-6 | Malignant | Serum | Age <8 | mean=171.3, sd=51.4, unit=ng/L | Table 2 row 2 |
| IL-8 | Malignant | Serum | Age >=8 | mean=727.1, sd=161.7, unit=ng/L | Table 2 row 1 |
| IL-8 | Malignant | Serum | Age <8 | mean=701.4, sd=166.6, unit=ng/L | Table 2 row 2 |
| IL-10 | Malignant | Serum | Age >=8 | mean=255.2, sd=49.69, unit=ng/L | Table 2 row 1 |
| IL-10 | Malignant | Serum | Age <8 | mean=242.6, sd=52.6, unit=ng/L | Table 2 row 2 |
| IL-6 | Malignant | Tissue | Positive | n=35, total=52, pct=67.3 | Results section paragraph 3 |
| IL-8 | Malignant | Tissue | Positive | n=40, total=52, pct=76.9 | Results section paragraph 3 |
| IL-10 | Malignant | Tissue | Positive | n=22, total=52, pct=42.3 | Results section paragraph 3 |
| Field | Value | Source |
|---|---|---|
| unpublished_individual_records | individual patient data not provided | Methods section |
| Field | Value | Source |
|---|---|---|
| cohort_size | total=18, males=9, females=9 | Methods, Animals |
| cohort_demographics | breeds=[Beagle], age_range=12-15mo, sex=9 males and 9 females, weight=7.5-11.5kg | Methods, Animals |
| endpoint_definition | Metabolic syndrome (MetS) markers including blood pressure, serum chemistry, lipoprotein profiling, blood glucose, glucagon, insulin, NT-proBNP, angiotensins, oxidative stress, and metabolomics | Abstract |
| study_design | Prospective, non-invasive, longitudinal preclinical model, isocaloric Western diet feeding for 10 weeks | Methods, Experimental design |
| data_granularity | summary_statistics_only | Methods, Statistics |
| Fasting blood glucose | All | BAS1 | median=88.0, iqr=82.0-91.0, unit=mg/dL, n=18 | Results, Fasting blood glucose, serum glucagon and insulin |
| Fasting blood glucose | All | BAS2 | median=102.5, iqr=95.0-109.0, unit=mg/dL, n=18, p<0.001 | Results, Fasting blood glucose, serum glucagon and insulin |
| Serum glucagon | All | BAS1 | median=69.3, iqr=64.0-77.2, unit=pg/mL, n=18 | Results, Fasting blood glucose, serum glucagon and insulin |
| Serum glucagon | All | BAS2 | median=61.8, iqr=49.8-64.3, unit=pg/mL, n=18, p=0.055 | Results, Fasting blood glucose, serum glucagon and insulin |
| AUC_ins(0-90) | All | BAS1 | median=202.7, iqr=103.1-276.8, unit=uIU/mL x min, n=18 | Results, Fasting blood glucose, serum glucagon and insulin |
| AUC_ins(0-90) | All | BAS2 | median=232.7, iqr=144.2-276.2, unit=uIU/mL x min, n=18, p=0.39 | Results, Fasting blood glucose, serum glucagon and insulin |
| SBP | All | BAS1 | median=133.5, iqr=126.0-141.0, unit=mmHg, n=18 | Results, Blood pressure |
| SBP | All | BAS2 | median=143.0, iqr=133.0-152.0, unit=mmHg, n=18, p=0.017 | Results, Blood pressure |
| NT-proBNP | All | BAS1 | median=250.0, iqr=250.0-401.0, unit=pmol/L, n=18 | Results, NT-proBNP |
| NT-proBNP | All | BAS2 | median=460.5, iqr=330.0-750.0, unit=pmol/L, n=18, p<0.001 | Results, NT-proBNP |
| Total cholesterol | All | BAS1 | median=130.0, iqr=125.0-145.0, unit=mg/dL, n=18 | Results, Total cholesterol, triglycerides and lipoproteins |
| Total cholesterol | All | BAS2 | median=187.5, iqr=173.0-219.0, unit=mg/dL, n=18, p<0.001 | Results, Total cholesterol, triglycerides and lipoproteins |
| Triglycerides | All | BAS1 | median=38.0, iqr=33.0-45.0, unit=mg/dL, n=18 | Results, Total cholesterol, triglycerides and lipoproteins |
| Triglycerides | All | BAS2 | median=37.5, iqr=34.0-48.0, unit=mg/dL, n=18, p=0.54 | Results, Total cholesterol, triglycerides and lipoproteins |
| Field | Value | Source |
|---|---|---|
| unpublished_individual_records | Individual animal data for all measured parameters were not published | Methods, Statistics |
| missing_analytes | Aldosterone data was not available for statistical analysis due to >45% of samples below LLOQ | Results, Renin-angiotensin aldosterone system (RAAS) |
| Field | Value | Source |
|---|---|---|
| cohort_size | total=80, control=40, tumor-bearing=40 | Methods, Study Design/Animals |
| cohort_demographics | control: median_age=5yr, range=3-15yr, sex=19M/21F; tumor-bearing: median_age=9.3yr, range=3-14yr, sex=23M/17F | Results, Clinical Patient Blood MDSC Evaluation; Table 1 |
| endpoint_definition | Percentage of cells staining positive for CD11b and CADO48A in peripheral blood | Methods, Statistical Analysis |
| study_design | Prospective observational study | Methods, Study Design/Animals |
| data_granularity | summary_statistics_only | Results, Table 2 |
| CD11b_low/CADO48A_low | Control | All | mean=3.6, sd=1.7, n=40 | Table 2 row 6 |
| CD11b_low/CADO48A_low | Tumor-bearing | All | mean=7.9, sd=3.0, n=40, p<0.048 | Table 2 row 6 |
| P2 (CD11b_hi/CADO48A_hi) | Control | All | mean=24.2, sd=9.2, n=40 | Table 2 row 4 |
| P2 (CD11b_hi/CADO48A_hi) | Tumor-bearing | All | mean=25.5, sd=12.8, n=40 | Table 2 row 4 |
| P3 (CD11b_hi/CADO48A_low) | Control | All | mean=4.6, sd=2.8, n=40 | Table 2 row 5 |
| P3 (CD11b_hi/CADO48A_low) | Tumor-bearing | All | mean=4.5, sd=3.6, n=40 | Table 2 row 5 |
| Field | Value | Source |
|---|---|---|
| unpublished_individual_records | Individual patient flow cytometry data not provided | Methods |
| missing_analytes | CBC and standard chemistry panels for study subjects | Methods |
| Field | Value | Source |
|---|---|---|
| Kinetic parameters | dog TK1 | dThd | Km=0.88, sd=0.1, Vmax=4.1, sd=0.1, kcat=1.81, sd=0.04, kcat/Km=2.05, n=1.3, sd=0.1 | Table 1 |
| Kinetic parameters | dog TK1 | AZT | Km=0.70, sd=0.1, Vmax=3.0, sd=0.1, kcat=1.32, sd=0.04, kcat/Km=1.89, n=1.4, sd=0.2 | Table 1 |
| Kinetic parameters | dog TK1 | ATP | Km=331, sd=1.0, Vmax=4.2, sd=0.3, kcat=1.85, sd=0.13, kcat/Km=0.006, n=2.4, sd=0.4 | Table 1 |
| Kinetic parameters | human TK1 | dThd | Km=0.83, sd=0.2, Vmax=2.5, sd=0.2, kcat=1.06, sd=0.08, kcat/Km=1.40, n=1.3, sd=0.4 | Table 1 |
| Kinetic parameters | human TK1 | AZT | Km=0.70, sd=0.2, Vmax=0.95, sd=0.06, kcat=0.40, sd=0.02, kcat/Km=0.62, n=1.4, sd=0.2 | Table 1 |
| Kinetic parameters | human TK1 | ATP | Km=243, Vmax=2.3, kcat=0.98, kcat/Km=0.004, n=2.3 | Table 1 |
| endpoint_definition | TK1 activity measured by radiochemical method and protein level by western blot | Methods section |
| study_design | in vitro characterization of recombinant, cellular, and serum TK1 | Abstract |
| data_granularity | summary_statistics_only | Methods section |
| Field | Value | Source |
|---|---|---|
| cohort_size | not_reported | Methods section |
| cohort_demographics | not_reported | Methods section |
| Field | Value | Source |
|---|---|---|
| cohort_size | total=12, healthy=4, mild_MVD=4, severe_MVD=4 | Methods, paragraph 1 |
| cohort_demographics | breed=[Cavalier King Charles Spaniel], age_range=1.5-11yr, sex=F/M/FS, weight=5-12kg | Table 1 |
| endpoint_definition | Diagnosis of MVD based on 2-D and colour Doppler echocardiographic findings: characteristic valvular lesions and demonstrated MR | Methods, paragraph 6 |
| study_design | prospective convenience sample | Methods, paragraph 1 |
| data_granularity | summary_statistics_only | Methods, Statistical analysis section |
| Serum_Sodium | Severe_MVD | Baseline | decreased, p=0.0228 (vs M), p=0.0256 (vs H) | Results, paragraph 3 |
| Serum_Calcium | Severe_MVD | Baseline | median=9.75, range=9-10.1, unit=mg/dl, p=0.0304 (vs H) | Table 3 |
| Complement_factor_H_isoform_2 | Mild_MVD | Baseline | down-regulated, p<=0.05 | Results, paragraph 5 |
| Inhibitor_of_carbonic_anhydrase | Mild_MVD | Baseline | down-regulated, p<=0.05 | Results, paragraph 5 |
| Hemopexin | Mild_MVD | Baseline | down-regulated, p<=0.05 | Results, paragraph 5 |
| Dystrobrevin_beta_isoform_X7 | Mild_MVD | Baseline | down-regulated, p<=0.05 | Results, paragraph 5 |
| CD5_molecule-like | Mild_MVD | Baseline | down-regulated, p<=0.05 | Results, paragraph 5 |
| Fibronectin_type-III_domain-containing_protein_3A_isoform_X4 | Mild_MVD | Baseline | up-regulated, p<=0.05 | Results, paragraph 5 |
| Calpain-3_isoform_X2 | Severe_MVD | Baseline | down-regulated, p<=0.05 | Results, paragraph 6 |
| L-2-hydroxyglutarate_dehydrogenase | Severe_MVD | Baseline | down-regulated, p<=0.05 | Results, paragraph 6 |
| Field | Value | Source |
|---|---|---|
| unpublished_individual_records | individual proteomic and clinical data not provided | Availability of data and materials |
| Field | Value | Source |
|---|---|---|
| cohort_size | total=55, multicenter=16, monocenter=39 | Results, paragraph 1 |
| cohort_demographics | breeds=large or giant breeds, age_range=8-10yr, sex=not_reported, weight=not_reported | Background, paragraph 1 |
| endpoint_definition | Survival time (ST), disease free interval (DFI), metastasis free interval (MFI), recurrence free interval (RFI) | Results, paragraph 1 |
| study_design | meta-analysis | Title |
| data_granularity | summary_statistics_only | Materials and methods, Statistical analysis |
| SALP_survival_time | elevated | all_studies | HR=1.62, 95pctCI=1.21-2.17, p=0.001 | Figure 1 |
| SALP_median_survival_time | elevated | all_studies | mean_diff=-156.4, 95pctCI=-208.7 to -104.1, p=0.000 | Figure 2 |
| SALP_disease_free_interval | elevated | all_studies | HR=1.96, 95pctCI=1.50-2.56, p=0.000 | Figure 3 |
| SALP_median_disease_free_interval | elevated | all_studies | mean_diff=-122.58, 95pctCI=-166.14 to -79.02, p=0.000 | Figure 4 |
| location_survival_time | proximal_humerus | all_studies | HR=1.86, 95pctCI=1.34-2.57, p=0.000 | Figure 5 |
| location_median_survival_time | proximal_humerus | all_studies | mean_diff=-131.58, 95pctCI=-210.81 to -52.35, p=0.001 | Figure 6 |
| location_disease_free_interval | proximal_humerus | all_studies | HR=2.53, 95pctCI=1.34-4.77 | Results, paragraph 5 |
| Field | Value | Source |
|---|---|---|
| unpublished_individual_records | individual patient data not provided | Materials and methods, Statistical analysis |
| missing_analytes | histological grade, histological subtype, infection status, percentage of bone length affected | Results, paragraph 2 |
| Field | Value | Source |
|---|---|---|
| cohort_size | total=53, diseased_Tollers=33, healthy_controls=20 | Methods section, Patients and Healthy controls paragraphs |
| cohort_demographics | breeds=[Nova Scotia duck tolling retriever], age_range=10mo-11yr, sex=17M/16F (diseased), weight=not_reported | Results section, Age and gender paragraph |
| endpoint_definition | clinical signs of musculoskeletal disorder (stiffness and pain from at least two joints) for at least 14 days | Methods section, Patients paragraph |
| study_design | clinical description and case-control study | Abstract |
| data_granularity | summary_statistics_only | Table 3 |
| Lymphocytes | diseased | baseline | mean=1.4, n=30, unit=10^9/L, p=0.004 | Table 3 |
| Lymphocytes | healthy_control | baseline | mean=1.9, n=20, unit=10^9/L | Table 3 |
| Fibrinogen | diseased | baseline | mean=2.7, n=24, unit=g/L, p=0.001 | Table 3 |
| Fibrinogen | healthy_control | baseline | mean=1.9, n=18, unit=g/L | Table 3 |
| alpha2-globulins | diseased | baseline | mean=12.1, n=31, unit=g/L, p=0.02 | Table 3 |
| alpha2-globulins | healthy_control | baseline | mean=10.8, n=20, unit=g/L | Table 3 |
| IIF-ANA_positive | diseased | baseline | 70pct, n=33 | Results section, ANA determination paragraph |
| Field | Value | Source |
|---|---|---|
| missing_analytes | joint fluid analysis | Discussion section, paragraph 2 |
| unpublished_individual_records | individual patient data for all clinical parameters | Methods section |
| Field | Value | Source |
|---|---|---|
| cohort_size | total=76, low_response_group=43-48, medium_response_group=14-22, high_response_group=8 | Results section paragraph 1 |
| cohort_demographics | age_median=8.2yr, weight_median=36kg, sex=FS 50.0pct, MC 46.1pct, F 1.3pct, M 2.6pct | Table 1 |
| endpoint_definition | DFS=time between treatment initiation and detection of tumor metastases; OS=time between treatment initiation and death | Methods section, Survival analysis |
| study_design | retrospective cohort study | Methods section, Study design |
| data_granularity | summary_statistics_only | Methods section |
| miR-214 | All | Baseline | HR=3.51, 95pctCI=1.68-8.55, p=0.0004, threshold_log2ACRQ>-0.92 | Table 2 |
| miR-126 | All | Baseline | HR=0.17, 95pctCI=0.0066-0.54, p=0.002, threshold_log2ACRQ>1.4 | Table 2 |
| ALP | All | Baseline | HR=1.97, 95pctCI=1.10-3.50, p=0.024, threshold>96U/L | Table 2 |
| Field | Value | Source |
|---|---|---|
| unpublished_individual_records | individual patient data not provided | Methods section |
| missing_timepoints | longitudinal follow-up miRNA levels not reported | Methods section |
| Field | Value | Source |
|---|---|---|
| cohort_size | total=47, healthy=20, mammary_tumors=27 | Methods section, Serum samples |
| cohort_demographics | healthy_age_range=3-10yr, mammary_tumor_age_range=3-14yr, sex=female, breeds=20_breeds_included | Methods section, Serum samples |
| endpoint_definition | sTK1 activity (pmol/min/mL) and sTK1 protein levels (ng/mL) | Results section, paragraph 1 |
| study_design | observational_case_control | Methods section |
| data_granularity | individual_animal_records | Table 1 and Table 2 |
| sTK1_activity | healthy | baseline | mean=0.73, sd=0.26, unit=pmol/min/mL | Table 1 |
| sTK1_protein | healthy | baseline | mean=8.5, sd=4, unit=ng/mL | Table 1 |
| sTK1_activity | CMT | baseline | mean=1.0, sd=0.36, unit=pmol/min/mL | Table 2 |
| sTK1_protein | CMT | baseline | mean=28.5, sd=11.4, unit=ng/mL | Table 2 |
| ROC_sTK1_activity | CMT_vs_healthy | AUC=0.74, p=0.0048, 95pctCI=0.59-0.88, sensitivity=0.22, specificity=0.95, threshold=1.32_pmol/min/mL | Results section, paragraph 2 |
| ROC_sTK1_protein | CMT_vs_healthy | AUC=0.96, p<0.0001, 95pctCI=0.92-1.01, sensitivity=0.81, specificity=0.95, threshold=17.5_ng/mL | Results section, paragraph 2 |
| Field | Value | Source |
|---|---|---|
| missing_timepoints | longitudinal_follow_up_data_not_reported | Discussion section, paragraph 2 |
| Field | Value | Source |
|---|---|---|
| cohort_size | total=67, survivors=42, non-survivors=25 | Results section paragraph 1; Table 3 |
| cohort_demographics | breeds=Table 1, age_median=12yr (IQR: 10-14yr), sex=28 females/39 males, weight_median=4.0kg (IQR: 3.0-7.3kg) | Results section paragraph 1; Table 1 |
| endpoint_definition | Survival for 30 days from the time of hospitalization | Abstract; Methods section |
| study_design | prospective observational study | Methods section |
| data_granularity | summary_statistics_only | Methods section; Results section |
| Neutrophil count | Survivor | 24h | median=12800, iqr=9225-16800, unit=cells/uL, n=38 | Table 3 |
| Neutrophil count | Non-survivor | 24h | median=17950, iqr=13750-22550, unit=cells/uL, n=20, p=0.01 | Table 3 |
| SCC | Survivor | 24h | median=4.8, iqr=3.7-8.6, unit=ug/dL, n=42 | Table 3 |
| SCC | Non-survivor | 24h | median=8.8, iqr=7.1-15.8, unit=ug/dL, n=20, p<0.001 | Table 3 |
| Inc-SCC | Survivor | 0-24h | median=-2.9, iqr=-10.6-0, unit=ug/dL, n=42 | Table 3 |
| Inc-SCC | Non-survivor | 0-24h | median=-0.25, iqr=-5.8-1.5, unit=ug/dL, n=20, p=0.02 | Table 3 |
| R-Inc-SCC | Survivor | 0-24h | median=0.51, iqr=0.34-1, unit=percent, n=42 | Table 3 |
| R-Inc-SCC | Non-survivor | 0-24h | median=0.99, iqr=0.57-1.2, unit=percent, n=20, p<0.001 | Table 3 |
| SCC | Mortality Prediction | Cutoff 6.6 ug/dL | AUC=0.72, sensitivity=89.5pct, specificity=61.9pct | Abstract; Results section paragraph 2; Fig 2d |
| SCC | Mortality Prediction | Multivariate OR | OR=4.93, 95pctCI=1.26-19.2, p=0.02 | Table 4 |
| Field | Value | Source |
|---|---|---|
| unpublished_individual_records | individual patient data not provided | Availability of data and materials |
| missing_timepoints | no data between 0 and 24 hours | Methods section |
| Field | Value | Source |
|---|---|---|
| cohort_size | not_reported | Table 1 |
| cohort_demographics | not_reported | Table 1 |
| endpoint_definition | Classification of dogs infected with Leishmania infantum into three groups based on clinical signs and APP (CRP and ferritin) concentrations | Table 1 |
| study_design | literature_review | Abstract |
| data_granularity | summary_statistics_only | Table 1 |
| CRP_and_ferritin | Group 1 | N/A | in_reference_range | Table 1 |
| CRP_and_ferritin | Group 2 | N/A | moderate_increase_in_one_or_both | Table 1 |
| CRP_and_ferritin | Group 3a | N/A | moderate_increase_in_one_or_both | Table 1 |
| CRP_and_ferritin | Group 3b | N/A | major_increase_in_one_or_both | Table 1 |
| Field | Value | Source |
|---|---|---|
| unpublished_individual_records | No individual animal data provided as this is a review article | Full text |
| missing_analytes | Specific numeric reference ranges for CRP and ferritin are not provided | Table 1 |
| missing_control_data | No healthy control group data provided | Table 1 |
| Field | Value | Source |
|---|---|---|
| cohort_size | total=18, Group 1=6, Group 2=12 | Results paragraph 1 and Table 1 |
| cohort_demographics | breeds=different, age_range=2-13yr, sex=13 males and 5 females | Results paragraph 1 |
| endpoint_definition | UPC reduction after 4 weeks of treatment with N-methylglucamine antimoniate and allopurinol | Methods section, Group allocation |
| study_design | prospective multicenter study | Methods section, Animals and sampling |
| data_granularity | summary_statistics_only | Table 1, Table 2, Table 3 |
| UPC | Group 1 | Initial | median=1.492, iqr=0.669-5.401 | Table 1 |
| UPC | Group 1 | Follow up | median=2.270, iqr=0.817-6.815 | Table 1 |
| UPC | Group 2 | Initial | median=1.318, iqr=0.830-3.087 | Table 1 |
| UPC | Group 2 | Follow up | median=0.432, iqr=0.215-1.038, p<0.001 | Table 1 |
| sCr | Group 1 | Initial | median=0.88, iqr=0.55-1.04, unit=mg/dL | Table 1 |
| sCr | Group 1 | Follow up | median=0.92, iqr=0.55-1.06, unit=mg/dL | Table 1 |
| sCr | Group 2 | Initial | median=0.69, iqr=0.51-0.92, unit=mg/dL | Table 1 |
| sCr | Group 2 | Follow up | median=0.94, iqr=0.66-1.09, unit=mg/dL | Table 1 |
| sSDMA | Group 1 | Initial | median=10.40, iqr=6.67-20.51, unit=μg/dL | Table 1 |
| sSDMA | Group 1 | Follow up | median=9.91, iqr=7.47-12.33, unit=μg/dL | Table 1 |
| sSDMA | Group 2 | Initial | median=10.95, iqr=7.85-16.35, unit=μg/dL | Table 1 |
| sSDMA | Group 2 | Follow up | median=11.15, iqr=8.57-12.18, unit=μg/dL | Table 1 |
| uIgG/Cr | Group 1 | Initial | median=202.7, iqr=31.1-4986.0, unit=mg/g | Table 2 |
| uIgG/Cr | Group 1 | Follow up | median=81.5, iqr=3.5-3603.0, unit=mg/g | Table 2 |
| uIgG/Cr | Group 2 | Initial | median=176.1, iqr=36.6-2996.0, unit=mg/g | Table 2 |
| uIgG/Cr | Group 2 | Follow up | median=40.4, iqr=12.9-408.4, p<0.01, unit=mg/g | Table 2 |
| uCRP/Cr | Group 1 | Initial | median=6.06, iqr=1.87-29.1, unit=μg/g | Table 2 |
| uCRP/Cr | Group 1 | Follow up | median=8.38, iqr=1.78-16.1, unit=μg/g | Table 2 |
| uCRP/Cr | Group 2 | Initial | median=15.40, iqr=4.624-74.67, unit=μg/g | Table 2 |
| uCRP/Cr | Group 2 | Follow up | median=3.21, iqr=2.48-5.09, p<0.01, unit=μg/g | Table 2 |
| uFerr/Cr | Group 1 | Initial | median=27.1, iqr=5.6-45.9, unit=μg/g | Table 2 |
| uFerr/Cr | Group 1 | Follow up | median=31.5, iqr=5.2-60.5, unit=μg/g | Table 2 |
| uFerr/Cr | Group 2 | Initial | median=23.48, iqr=8.95-60.92, unit=μg/g | Table 2 |
| uFerr/Cr | Group 2 | Follow up | median=13.71, iqr=5.35-30.57, p<0.05, unit=μg/g | Table 2 |
| uRBP/Cr | Group 1 | Initial | median=0.880, iqr=0.049-7.453, unit=mg/g | Table 3 |
| uRBP/Cr | Group 1 | Follow up | median=0.506, iqr=0.173-8.608, unit=mg/g | Table 3 |
| uRBP/Cr | Group 2 | Initial | median=0.484, iqr=0.227-2.650, unit=mg/g | Table 3 |
| uRBP/Cr | Group 2 | Follow up | median=0.169, iqr=0.037-0.502, p<0.05, unit=mg/g | Table 3 |
| uNAG/Cr | Group 1 | Initial | median=18.49, iqr=4.35-98.82, unit=UI/g | Table 3 |
| uNAG/Cr | Group 1 | Follow up | median=18.30, iqr=5.64-28.57, unit=UI/g | Table 3 |
| uNAG/Cr | Group 2 | Initial | median=14.77, iqr=5.31-28.32, unit=UI/g | Table 3 |
| uNAG/Cr | Group 2 | Follow up | median=6.20, iqr=3.84-14.56, p<0.05, unit=UI/g | Table 3 |
| uGGT/Cr | Group 1 | Initial | median=31.3, iqr=20.0-101.8, unit=UI/g | Table 3 |
| uGGT/Cr | Group 1 | Follow up | median=28.4, iqr=9.9-95.2, unit=UI/g | Table 3 |
| uGGT/Cr | Group 2 | Initial | median=15.38, iqr=11.05-90.36, unit=UI/g | Table 3 |
| uGGT/Cr | Group 2 | Follow up | median=10.78, iqr=7.44-19.63, unit=UI/g | Table 3 |
| Field | Value | Source |
|---|---|---|
| unpublished_individual_records | individual animal data not provided | Methods section |
| Field | Value | Source |
|---|---|---|
| CRP | Dog | Saliva | correlation=0.87, unit=micrograms/L, ref_range=not_reported, p=not_reported | Section: Saliva: a novel biological sample, paragraph 1 |
| endpoint_definition | Review of acute phase proteins, saliva as a diagnostic sample, and veterinary laboratory education | Abstract |
| study_design | literature_review | Abstract |
| data_granularity | summary_statistics_only | Entire document |
| Field | Value | Source |
|---|---|---|
| cohort_size | not_reported | not_reported |
| cohort_demographics | not_reported | not_reported |
| missing_analytes | No specific clinical trial data provided for analytes | Entire document |
| missing_control_data | No control group data provided | Entire document |
| Field | Value | Source |
|---|---|---|
| cohort_size | total=53, sepsis_without_organ_dysfunction=18, severe_sepsis=24, septic_shock=11 | Results, paragraph 1 |
| cohort_demographics | age_range=0.08-15.5yr, sex=22 intact female, 5 spayed female, 22 intact male, 4 castrated male, weight_range=3.7-55.7kg | Results, paragraph 1 |
| endpoint_definition | survival to hospital discharge, death, or euthanasia for disease severity | Materials and methods, Illness severity and outcome classification |
| study_design | prospective observational study | Materials and methods, Animals |
| data_granularity | summary_statistics_only | Results, paragraph 1 |
| Procalcitonin | Sepsis | T0 | median=103.0, min=15.4, max=470.2, unit=pg/mL, n=53 | Results, paragraph 2 |
| Procalcitonin | Healthy Controls | T0 | median=41.6, min=21.5, max=88.7, unit=pg/mL, n=12 | Results, paragraph 2 |
| Procalcitonin | Septic Shock | T0 | median=243.1, min=56.7, max=369.8, unit=pg/mL, n=11 | Results, paragraph 2 |
| Procalcitonin | Sepsis without cardiovascular compromise | T0 | median=77, min=18.2, max=470.2, unit=pg/mL, n=42 | Results, paragraph 2 |
| Procalcitonin | Survivors | T0 | median=87.64, min=15.39, max=470.2, unit=pg/mL, n=38 | Results, paragraph 2 |
| Procalcitonin | Non-survivors | T0 | median=150.2, min=26.34, max=369.8, unit=pg/mL, n=15 | Results, paragraph 2 |
| Procalcitonin | Survivors | T1 | median=42.5, min=7.5, max=432.7, unit=pg/mL | Results, paragraph 3 |
| Procalcitonin | Survivors | T2 | median=41.9, min=3.9, max=559.3, unit=pg/mL | Results, paragraph 3 |
| Procalcitonin clearance | Survivors | 24h | median=44, iqr=-38 to 82, unit=percent, p=0.037 | Results, paragraph 3 |
| Procalcitonin clearance | Non-survivors | 24h | median=1, iqr=-39 to 62, unit=percent, p=0.037 | Results, paragraph 3 |
| Field | Value | Source |
|---|---|---|
| unpublished_individual_records | individual patient data not provided | Materials and methods |
| missing_timepoints | serial data not available for all 53 dogs at T1 and T2 | Results, paragraph 3 |
| Field | Value | Source |
|---|---|---|
| cohort_size | total=60, LBCL=60 | Section 4.1.2 |
| cohort_demographics | breeds=not_reported, age_range=not_reported, sex=not_reported, weight=not_reported | Section 4.1.2 |
| endpoint_definition | PB infiltration = percentage of large CD21-positive cells out of total CD45-positive cells; BM infiltration = percentage of large CD21-positive cells out of total CD45-positive cells | Section 4.1 |
| study_design | retrospective | Section 4.1.2 |
| data_granularity | summary_statistics_only | Section 5.1.2 |
| BM_infiltration_LBCL | LBCL | baseline | mean=11.17, sd=20.45, median=1.04, unit=pct, n=20 | Section 5.1.1 |
| PB_infiltration_LBCL | LBCL | baseline | mean=6.47, sd=16.72, median=1.77, unit=pct, n=29 | Section 5.1.1 |
| Field | Value | Source |
|---|---|---|
| missing_individual_records | individual animal records for the 60 LBCL cases are not provided | Section 4.1.2 |
| missing_demographics | age, sex, and breed distribution for the 60 LBCL cases are not reported | Section 4.1.2 |
| Field | Value | Source |
|---|---|---|
| endpoint_definition | treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD) | Abstract |
| study_design | patent_specification | Full text |
| Field | Value | Source |
|---|---|---|
| cohort_size | not_reported | Full text |
| cohort_demographics | not_reported | Full text |
| data_granularity | not_reported | Full text |
| missing_analytes | all clinical chemistry and biomarker data | Full text |
| Field | Value | Source |
|---|---|---|
| endpoint_definition | worsening kidney disease defined by incremental increases in NGAL levels over time | Abstract |
| study_design | diagnostic method patent | Abstract |
| Field | Value | Source |
|---|---|---|
| cohort_size | not_reported | entire document |
| cohort_demographics | not_reported | entire document |
| data_granularity | not_reported | entire document |
| missing_analytes | NGAL concentration values, serum creatinine values, urine protein levels, GFR values | entire document |
| missing_control_data | no control group data provided | entire document |
| Field | Value | Source |
|---|---|---|
| endpoint_definition | Diagnosis of chronic kidney disease (CKD) or glomerulopathy based on urine levels of ALB, SERPINA1, ORM1, TF, and TFF1. | Abstract |
| study_design | Diagnostic method development | Abstract |
| Field | Value | Source |
|---|---|---|
| cohort_size | not_reported | US-2023137242-A1 |
| cohort_demographics | not_reported | US-2023137242-A1 |
| data_granularity | not_reported | US-2023137242-A1 |
| missing_analytes | All quantitative values for ALB, SERPINA1, ORM1, TF, and TFF1 are missing. | US-2023137242-A1 |